Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome2011 · 36 citations
2. 2Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development2017 · 63 citations
3. 3Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura2010 · 76 citations
4. 4Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura2016 · 126 citations
5. 5Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura2014 · 190 citations